ArticleCancer diagnosis & prognosis
External Validation of an Extended Prognostic Assessment Model in Patients With Brain Metastases from Small-cell Lung Cancer.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable Machine Learning for Survival Prediction in Small Cell Lung Cancer Patients With Brain Metastases: A Population-Based Study With External Validation.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Recently, the small-cell lung cancer (SCLC) grade model for patients with brain metastases was developed by a Japanese group. It includes sex, performance status, number of brain metastases, primary tumor control and presence of extracranial metastases. The aim of the present study was to validate this prognostic score in a European cohort of patients. Patients and Methods: The retrospective validation study included 189 patients from two centers in Germany and Norway. Survival according to the SCLC grade score was evaluated. Additional prognostic factors were analyzed. Results: Median survival was 7.5 months. The 3-tiered SCLC grade score based on the sum of adverse prognostic features was significantly associated with survival ( Conclusion: This validation study supports the international applicability of the SCLC grade model. Age, which has also been identified as a relevant prognostic factor in other previous studies (including the SCLC Graded Prognostic Assessment), may deserve consideration when trying to optimize survival prediction. Given that different studies identified different age limits,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.